4//SEC Filing
Gaiero David G 4
Accession 0001209191-23-056425
CIK 0001662244other
Filed
Nov 21, 7:00 PM ET
Accepted
Nov 22, 1:47 PM ET
Size
11.6 KB
Accession
0001209191-23-056425
Insider Transaction Report
Form 4
Gaiero David G
Vice President, Finance
Transactions
- Exercise/Conversion
Common Stock
2023-11-20$1.68/sh+52,584$88,341→ 66,684 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-11-20−52,584→ 21,055 totalExercise: $1.68Exp: 2030-12-10→ Common Stock (52,584 underlying) - Exercise/Conversion
Common Stock
2023-11-20$1.69/sh+21,356$36,092→ 88,040 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-11-20−21,356→ 92,544 totalExercise: $1.69Exp: 2033-02-03→ Common Stock (21,356 underlying)
Footnotes (3)
- [F1]Includes 5,000 shares of the Company's common stock pursuant to the Cyteir Therapeutics, Inc. Employee Stock Purchase Program ("ESPP"). In accordance with the ESPP, these shares were purchased based on 85% of the closing stock price on January 17, 2023.
- [F2]The option vested as to 25% of the underlying shares of common stock on December 7, 2021, the first anniversary of the vesting commencement date, and vests as to 1/48th of the underlying shares thereafter on each subsequent monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.
- [F3]The option vests as to 1/48th of the underlying shares thereafter on each subsequent monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.
Documents
Issuer
Cyteir Therapeutics, Inc.
CIK 0001662244
Entity typeother
Related Parties
1- filerCIK 0001799784
Filing Metadata
- Form type
- 4
- Filed
- Nov 21, 7:00 PM ET
- Accepted
- Nov 22, 1:47 PM ET
- Size
- 11.6 KB